Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Altria Group Inc (MO) vs Revvity Inc (RVTY) Price & Performance

Altria Group IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Altria Group Inc vs Revvity Inc — how do they compare? Altria Group Inc trades at $65.05 (market cap $114.13B), while Revvity Inc trades at $115.76 (market cap $12.94B). The key difference: Altria Group Inc is far larger — about 8.8× Revvity Inc's market cap, and Altria Group Inc pays the higher dividend (6.2%). Which is the better fit depends on your goals.

MORVTY
Market Cap
$114.13B$12.94B
Sector
Consumer StaplesTechnology
52-Week High
$74.92$117.75
52-Week Low
$54.72$82.26
Enterprise Value
$136.34B$15.26B
Dividend Yield
6.2%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Altria Group Inc

Altria Group (MO) trades at $68.35, up 0.89% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains strong profitability with 39% net income margin and $6.95B net income for 2025, though revenue declined slightly to $20.14B. Recent earnings show alternating beats and misses, with Q3 2026 results pending. Analyst consensus remains bullish with 61.5% buy ratings and $71.50 price target, while the stock offers a 6.3% dividend yield with 56 consecutive annual increases expected.

MO presents value opportunity with 14.4x P/E ratio and strong cash flow generation, but faces headwinds from cigarette volume declines and regulatory pressures. The smoke-free product transition shows progress but remains early stage. Current price near support at $67 suggests limited downside, while analyst targets indicate 4.6% upside potential. Key risks include litigation exposure and slower-than-expected diversification from traditional tobacco products.

Revvity Inc

RVTY trades at $114.66, up 0.37% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 54.98% gross margin and $241.20M net income for 2025, supported by positive news including product launches and raised 2026 guidance. Analyst consensus is a buy with a $120.50 price target, indicating potential upside from current levels.

Outlook remains positive due to consistent earnings outperformance and innovation in diagnostics, but risks include high P/E valuation and competitive pressures. Investors may find opportunity in sustained margin strength and AI integration, though macroeconomic sensitivity warrants caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

Read more on MO

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY